Immuntep SA

Immutep S.A. is a biopharmaceutical company developing technologies for novel immunotherapies for the treatment of cancer and chronic infectious diseases and new approaches to immune response modulation. The Company's technologies are based on the properties of LAG-3. Immutep is developing its products both in-house and in partnership with pharmaceutical and biotech companies. The Company was formed in 2001 by Frédéric Triebel, the scientific founder, and John B. Hawken, a specialist in the management of biotech start-ups, and has its headquarters and research facilities near Paris, France. Immutep is backed by the Paris-based venture capital firm Innoven Partenaires and the venture capital fund H2I, a specialist Biotech fund managed by Unicorn Biotutors/Equitis (Paris).